LDL-TG Biomarker Detection for Cardiovascular Risk

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for diagnosing cardiovascular disease are invasive or lack sensitivity in predicting risk, particularly for atherosclerotic coronary artery disease, and fail to account for the role of triglyceride-rich LDL particles in atherosclerosis.

Innovation Solution

Non-invasive methods involving the determination of LDL-triglycerides (LDL-TG) and other biomarkers such as triglycerides, total cholesterol, HDL-cholesterol, apoB, IL-6, SDMA, apoB48, POA, sd-LDL, and ADMA in blood samples to identify individuals at risk of cardiovascular disease, using mass spectrometry and statistical analysis to assess elevations compared to control levels.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If current diagnostic methods are used for cardiovascular disease, then the diagnostic process is invasive or lacks sensitivity, but the ability to predict risk accurately is insufficient

Engineering Contradiction:

Improvesensitivity in predicting cardiovascular riskVSAvoidinvasiveness of diagnostic procedure

Core Design Contradiction:

Measurement precisionVSEase of operation

Solution Approach 1:

The patent replaces invasive mechanical diagnostic procedures with a biochemical analysis system using mass spectrometry to measure LDL-TG and other biomarkers in blood samples, achieving high sensitivity without invasive intervention

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The patent uses LDL-TG and other biomarkers as intermediary substances that mediate between the physiological state (atherosclerosis risk) and the diagnostic measurement, allowing indirect but sensitive detection of cardiovascular risk

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If traditional biomarker panels are used, then the diagnostic approach is simple, but it fails to account for triglyceride-rich LDL particles in atherosclerosis

Engineering Contradiction:

Improveaccuracy in predicting cardiovascular riskVSAvoidcomplexity of biomarker analysis panel

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent segments the traditional cholesterol measurement into distinct components including LDL-TG, LDL-C, HDL-C, and other specific biomarkers, allowing separate measurement and evaluation of each component's contribution to cardiovascular risk

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent changes the measurement parameter from traditional total cholesterol to specific triglyceride-rich LDL particle measurements and other biomarker concentrations, providing more reliable risk prediction through expanded parameter measurement

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

These methods provide a sensitive and non-invasive means to predict cardiovascular disease risk by identifying elevated biomarker levels, enabling early detection and potential treatment intervention.

Implementation Method 1

using mass spectrometry and statistical analysis to assess elevations compared to control levels

Methodology Applied

Scientific EffectMass spectrometry:

Data Source

PatentUS11513131B2Low density lipoprotein triglycerides (LDL-TG) as a biomarker of cardiovascular disease and uses thereof

Publication Date: 2022.11.29 GLOBAL GENOMICS GRP LLC

AI summary

The invention, in some aspects, relates to methods for diagnosing cardiovascular disease, and/or detecting cardiovascular disease in a patient, and more particularly to methods of using blood-based biomarkers and their combinations to identify patients at risk of having cardiovascular disease (e.g., coronary atherosclerosis).